# Adaptable and scalable electroporation for cellular therapy

> **NIH NIH R44** · CYTEQUEST, INC. · 2024 · $1,002,657

## Abstract

Project Summary/Abstract
Cellular therapies, in which living cells are the drug administered to patients, have the potential to advance treatment for a
variety of inherited and acquired diseases. In particular, chimeric antigen receptor (CAR)-T therapies have shown
remarkable efficacy in certain hematological cancers. The first generation of approved CAR-T therapies rely on viral
vectors for cellular reprogramming. Viral vectors have enabled the transduction of tough-to-transfect primary T cells but
have several drawbacks related to their relatively lengthy manufacturing processes, immunogenicity, and potential for
insertional mutagenesis. Furthermore, the field is trending towards more complex reprogramming methods, such as
multiple gene edits via CRISPR technology, that are not compatible with typical packaging limits associated with viral
approaches. Electroporation is a well-known method for delivery of DNA, RNA, and proteins into cells, that is recognized
as the leading replacement for viral delivery. CyteQuest is dedicated to address the need for a flexible electroporation
platform that can facilitate discovery and easily scale cell therapy manufacturing from the research level (low-volume) to
the clinical level (high-volume). CyteQuest has developed a scalable electroporation platform to optimize transfection
parameters and deliver cargo efficiently and reproducibly at high throughput. The platform incorporates a single use,
continuous-flow fluidic system designed to integrate with automated cell processing approaches. The key objectives of
this proposal are to: (1) design, construct, and test optimization instrument prototypes capable of multiplexed
electroporation (up to parallel 8 channels) to enable rapid optimization of transfection parameters and use these
instruments with academic and clinical collaborators to advance their cell therapy programs; and (2) design, construct and
test manufacturing instrument prototypes capable of rapid delivery of cargo to mid and high volumes of cells to enable
GMP-compatible cell manufacturing within a closed system. CyteQuest’s goal is to expand the availability of cellular
therapy to treat a wider range of diseases and extend treatment to a much broader patient community.

## Key facts

- **NIH application ID:** 11006102
- **Project number:** 2R44GM148147-02A1
- **Recipient organization:** CYTEQUEST, INC.
- **Principal Investigator:** HAROLD G CRAIGHEAD
- **Activity code:** R44 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $1,002,657
- **Award type:** 2
- **Project period:** 2022-07-01 → 2026-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11006102

## Citation

> US National Institutes of Health, RePORTER application 11006102, Adaptable and scalable electroporation for cellular therapy (2R44GM148147-02A1). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/11006102. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*